BRPI0605925A2 - processo de modulação de funcionamento de célula t - Google Patents

processo de modulação de funcionamento de célula t

Info

Publication number
BRPI0605925A2
BRPI0605925A2 BRPI0605925-2A BRPI0605925A BRPI0605925A2 BR PI0605925 A2 BRPI0605925 A2 BR PI0605925A2 BR PI0605925 A BRPI0605925 A BR PI0605925A BR PI0605925 A2 BRPI0605925 A2 BR PI0605925A2
Authority
BR
Brazil
Prior art keywords
modulation process
cell operation
mammal
modulation
cell functioning
Prior art date
Application number
BRPI0605925-2A
Other languages
English (en)
Inventor
Lawrence Steinman
Michael Platten
Peggy Pui-Kay Ho
Michael L Selley
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of BRPI0605925A2 publication Critical patent/BRPI0605925A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

PROCESSO DE MODULAçãO DE FUNCIONAMENTO DE CéLULA T. Um processo de modulação de funcionamento de célula THI em um mamífero, compreendendo administração ao dito mamífero de uma quantidade efetiva de um ou mais metabálitos de triptofano mediados por IDO ou seus derivados; ou um seu antagonista.
BRPI0605925-2A 2005-01-14 2006-01-12 processo de modulação de funcionamento de célula t BRPI0605925A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64450205P 2005-01-14 2005-01-14
PCT/US2006/001241 WO2006076580A2 (en) 2005-01-14 2006-01-12 A method of modulating t cell functioning

Publications (1)

Publication Number Publication Date
BRPI0605925A2 true BRPI0605925A2 (pt) 2009-05-26

Family

ID=36678226

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0605925-2A BRPI0605925A2 (pt) 2005-01-14 2006-01-12 processo de modulação de funcionamento de célula t

Country Status (10)

Country Link
EP (2) EP2253313A1 (pt)
JP (1) JP2008526983A (pt)
KR (1) KR20070098916A (pt)
CN (1) CN101232878A (pt)
AU (1) AU2006204871A1 (pt)
BR (1) BRPI0605925A2 (pt)
CA (1) CA2594460A1 (pt)
IL (1) IL184523A0 (pt)
WO (1) WO2006076580A2 (pt)
ZA (1) ZA200706751B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2030617A1 (en) * 2007-08-17 2009-03-04 Sygnis Bioscience GmbH & Co. KG Use of tranilast and derivatives thereof for the therapy of neurological conditions
FR3055548B1 (fr) * 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
CN110607335B (zh) * 2018-06-14 2021-08-03 中国科学院微生物研究所 一种烟酰胺腺嘌呤二核苷酸类化合物生物合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5640710B2 (pt) 1973-01-18 1981-09-22
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
US20050239892A1 (en) * 2003-11-21 2005-10-27 Trustees Of Tufts College Therapeutic avenathramide compounds
CA2587407A1 (en) * 2004-11-17 2006-05-26 Angiogen Pharmaceuticals Pty. Ltd. A method of modulating b cell functioning

Also Published As

Publication number Publication date
CN101232878A (zh) 2008-07-30
ZA200706751B (en) 2008-10-29
AU2006204871A1 (en) 2006-07-20
EP2253313A1 (en) 2010-11-24
JP2008526983A (ja) 2008-07-24
CA2594460A1 (en) 2006-07-20
WO2006076580A3 (en) 2007-07-12
EP1845967A4 (en) 2008-03-05
EP1845967A2 (en) 2007-10-24
WO2006076580A2 (en) 2006-07-20
KR20070098916A (ko) 2007-10-05
IL184523A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
BR112012013847A2 (pt) novos derivados de indolinona ciclopropano
UY31789A1 (es) Composiciones de insulina de super rápida actuación
BR112013004362A2 (pt) aparelho para a geração de um sinal descorrelacionado utilizando informação de fase transmitida
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
NO20082793L (no) Nye tiofenderivater
CY1112483T1 (el) Αγωνιστες gpcr πιπεριδινης
NO20084278L (no) Bezothiazol derivatives as beta2 adrenoreceptor agonists
ES2421613T3 (es) Composición farmacéutica externa
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
HK1158192A1 (en) Piperidine gpcr agonists
NO20083462L (no) Nye tiofenderivater som S1P1/EDG1-reseptoragonister
DK1959951T3 (da) Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
HN2011001446A (es) Compuesto utiles para inhibir chk1
GT200500246A (es) Combinacion de compuestos organicos
AR059696A1 (es) Medicamentos que contienen fluoroquinolonas
CR11363A (es) Composicion de zibotentan que contiene manitol y/ o celulosa microcristalina
BR112012006172A2 (pt) derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia
NO20080158L (no) Oyedraper som inneholder roflumilast
RS53586B1 (en) DERIVATION OF DECISION
CL2009001298A1 (es) Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4.
MA31383B1 (fr) Composés pontés de cycles à six chaînons
DK2049480T3 (da) 2-arylindolderivater som mPGES-1-hæmmere
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
ECSP099754A (es) Derivados de la espirociclopropil piperidina
GT200600334A (es) Proceso para la sintesis de los moduladores del receptor de progesterona

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.